4.72
0.06 (1.29%)
| Previous Close | 4.66 |
| Open | 4.65 |
| Volume | 1,303,874 |
| Avg. Volume (3M) | 3,255,008 |
| Market Cap | 1,292,899,328 |
| Price / Sales | 212.62 |
| Price / Book | 5.64 |
| 52 Weeks Range | |
| Earnings Date | 4 Nov 2025 |
| Operating Margin (TTM) | -930.54% |
| Diluted EPS (TTM) | -0.340 |
| Quarterly Revenue Growth (YOY) | -32.50% |
| Total Debt/Equity (MRQ) | 111.93% |
| Current Ratio (MRQ) | 5.35 |
| Operating Cash Flow (TTM) | -83.45 M |
| Levered Free Cash Flow (TTM) | -52.28 M |
| Return on Assets (TTM) | -35.91% |
| Return on Equity (TTM) | -159.34% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Taysha Gene Therapies, Inc. | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | -4.0 |
| Price Volatility | -4.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Average | -0.90 |
|
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 12.11% |
| % Held by Institutions | 67.23% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Avoro Capital Advisors Llc | 30 Sep 2025 | 21,700,000 |
| Siren, L.L.C. | 30 Sep 2025 | 11,014,737 |
| Octagon Capital Advisors Lp | 30 Sep 2025 | 9,067,500 |
| Vestal Point Capital, Lp | 30 Sep 2025 | 5,500,000 |
| Deerfield Management Company, L.P. | 30 Sep 2025 | 5,386,000 |
| Polar Capital Holdings Plc | 30 Sep 2025 | 5,293,879 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 12.00 (Chardan Capital, 154.24%) | Buy |
| Median | 11.00 (133.05%) | |
| Low | 8.00 (Citizens, 69.49%) | Buy |
| Average | 10.33 (118.86%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 4.73 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Chardan Capital | 06 Jan 2026 | 12.00 (154.24%) | Buy | 5.26 |
| 05 Nov 2025 | 12.00 (154.24%) | Buy | 4.03 | |
| Wells Fargo | 05 Jan 2026 | 11.00 (133.05%) | Buy | 4.89 |
| Citizens | 05 Nov 2025 | 8.00 (69.49%) | Buy | 4.03 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| ALAM KAMRAN | - | 4.69 | -102,817 | -480,558 |
| NAGENDRAN SUKUMAR | - | 4.69 | -116,050 | -542,408 |
| NOLAN SEAN P. | - | 4.69 | -178,101 | -832,429 |
| Aggregate Net Quantity | -396,968 | |||
| Aggregate Net Value ($) | -1,855,396 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 4.69 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| ALAM KAMRAN | Officer | 26 Jan 2026 | Sell (-) | 23,849 | 4.72 | 112,567 |
| NOLAN SEAN P. | Officer | 26 Jan 2026 | Sell (-) | 41,312 | 4.72 | 194,993 |
| NAGENDRAN SUKUMAR | Officer | 26 Jan 2026 | Sell (-) | 26,918 | 4.72 | 127,053 |
| ALAM KAMRAN | Officer | 23 Jan 2026 | Sell (-) | 78,968 | 4.66 | 367,991 |
| NOLAN SEAN P. | Officer | 23 Jan 2026 | Sell (-) | 136,789 | 4.66 | 637,437 |
| NAGENDRAN SUKUMAR | Officer | 23 Jan 2026 | Sell (-) | 89,132 | 4.66 | 415,355 |
| Date | Type | Details |
|---|---|---|
| 06 Jan 2026 | Announcement | Taysha Gene Therapies Announces Progress Across TSHA-102 Pivotal Gene Therapy Program in Rett Syndrome |
| 05 Dec 2025 | Announcement | Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) |
| 04 Nov 2025 | Announcement | Taysha Gene Therapies Reports Third Quarter 2025 Financial Results and Provides Corporate Update |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |